Update on cancer therapeutics最新文献_第8页

Cancer imaging and therapy with bispecific antibody pretargeting 双特异性抗体预靶向的肿瘤成像和治疗

Update on cancer therapeutics Pub Date : 2007-03-01 DOI: 10.1016/j.uct.2007.04.003

David M. Goldenberg , Jean-Francois Chatal , Jacques Barbet , Otto Boerman , Robert M. Sharkey

{"title":"Cancer imaging and therapy with bispecific antibody pretargeting","authors":"David M. Goldenberg , Jean-Francois Chatal , Jacques Barbet , Otto Boerman , Robert M. Sharkey","doi":"10.1016/j.uct.2007.04.003","DOIUrl":"10.1016/j.uct.2007.04.003","url":null,"abstract":"<div><p><span><span><span>This article reviews recent preclinical and clinical advances in the use of pretargeting methods for the radioimmunodetection and </span>radioimmunotherapy<span> of cancer. Whereas directly labeled antibodies, fragments, and subfragments (minibodies and other constructs) have shown promise in both imaging and therapy applications over the past 25 years, their clinical adoption has not fulfilled the original expectations due to either poor image resolution and contrast in scanning or insufficient radiation doses delivered selectively to tumors for therapy. Pretargeting involves the separation of the localization of tumor with an anticancer antibody from the subsequent delivery of the imaging or therapeutic </span></span>radionuclide<span>. This has shown improvements in both imaging and therapy by overcoming the limitations of conventional, or one-step, radioimmunodetection or radioimmunotherapy. We focus herein on the use of bispecific antibodies followed by radiolabeled peptide </span></span>haptens as a new modality of selective delivery of radionuclides for the imaging and therapy of cancer. Our particular emphasis in pretargeting is the use of bispecific trimeric (three Fab′s) recombinant constructs made by a modular method of antibody and protein engineering of fusion molecules called dock and lock (DNL).</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2007.04.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27296674","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 90

Combining vaccines with conventional therapies for cancer 将疫苗与传统癌症疗法相结合

Update on cancer therapeutics Pub Date : 2007-03-01 DOI: 10.1016/j.uct.2007.04.004

Philip M. Arlen, Ravi A. Madan, James W. Hodge, Jeffrey Schlom, James L. Gulley

{"title":"Combining vaccines with conventional therapies for cancer","authors":"Philip M. Arlen, Ravi A. Madan, James W. Hodge, Jeffrey Schlom, James L. Gulley","doi":"10.1016/j.uct.2007.04.004","DOIUrl":"10.1016/j.uct.2007.04.004","url":null,"abstract":"<div><p><span><span>Preclinical and clinical investigations currently underway are employing novel strategies for combining vaccines with conventional and experimental anticancer therapies. To date, the FDA has not approved a therapeutic </span>cancer vaccine. However, the results of recent investigations suggest an increasing role for vaccines in new models of combination therapy for many types of cancer. This article reviews and discusses therapeutic cancer strategies that employ vaccines in combination with local radiation, chemotherapy, </span>hormone therapy<span><span>, and anti-CTLA-4 mAb. Preclinical studies<span> have shown that certain anticancer agents have immune modulatory effects that result in up-regulation of surface expression of MHC molecules, tumor-associated antigens, or Fas on malignant cells, rendering them more susceptible to immune destruction. Preliminary results of clinical studies using combination strategies have demonstrated a postvaccination antigen cascade, prolonged time to </span></span>disease progression, and improved overall survival. Several larger randomized trials are ongoing, and more are required to support these findings.</span></p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2007.04.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27057621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 24

NSC-Numbers 国家标准编号

Update on cancer therapeutics Pub Date : 2007-03-01 DOI: 10.1016/S1872-115X(07)00011-4

引用次数: 0

Biological Abbreviations 生物的缩写

Update on cancer therapeutics Pub Date : 2007-03-01 DOI: 10.1016/S1872-115X(07)00010-2

引用次数: 0

Copyright text 版权文本

Update on cancer therapeutics Pub Date : 2007-03-01 DOI: 10.1016/S1872-115X(07)00007-2

引用次数: 0

Neuroendocrine tumours 神经内分泌肿瘤

Update on cancer therapeutics Pub Date : 2007-03-01 DOI: 10.1016/j.uct.2007.04.001

Dan Granberg, Kjell Öberg

{"title":"Neuroendocrine tumours","authors":"Dan Granberg, Kjell Öberg","doi":"10.1016/j.uct.2007.04.001","DOIUrl":"https://doi.org/10.1016/j.uct.2007.04.001","url":null,"abstract":"<div><p>Neuroendocrine tumours can be divided into endocrine neoplasms occurring in the lungs, thymus, gastrointestinal tract and pancreas. Most neuroendocrine tumours are slowly growing neoplasms, but some of them are highly malignant and show an aggressive behaviour. A special feature of neuroendocrine tumours is the ability to produce peptides or hormones, for example, serotonin, histamine, ACTH, VIP, insulin, proinsulin, glucagon or calcitonin, thereby giving rise to disabling endocrine syndromes such as the carcinoid syndrome, an atypical carcinoid syndrome, ectopic Cushing's syndrome, the WDHA-syndrome, the insulinoma syndrome or the glucagonoma syndrome. The treatment of patients with neuroendocrine tumours consists of surgery, radiotherapy, biotherapy, chemotherapy and local ablative treatments such as liver embolization and radiofrequency ablation. Nearly all patients should be considered for surgery, which is the only curative treatment but may also be used for debulking of metastases. Radiotherapy may either be given as conventional radiotherapy, usually against bone or brain metastases, or as targeted irradiation therapy with <sup>111</sup>Indium-, <sup>90</sup>Yttrium- or <sup>177</sup>Lutetium-labelled somatostatin analogues. Biotherapy traditionally consists of alpha-interferon and somatostatin analogues, which may show antitumoural activity and relieve endocrine symptoms. Today, several new biological agents have been introduced such as tyrosine kinase inhibitors, mTOR inhibitors and antiangiogenic agents. Various chemotherapy combinations are used in patients with endocrine pancreatic tumours, lung and thymic carcinoids and in patients with highly aggressive neuroendocrine tumours. Most patients with neuroendocrine tumours have a relatively good prognosis with long expected survival, but the prognosis in patients with poorly differentiated neuroendocrine tumours is poor.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2007-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2007.04.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136849670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Abbreviations of drugs 药物简写

Update on cancer therapeutics Pub Date : 2007-03-01 DOI: 10.1016/S1872-115X(07)00008-4

引用次数: 0

Tubulin Targeting Agents 微管蛋白靶向剂

Update on cancer therapeutics Pub Date : 2007-03-01 DOI: 10.1016/j.uct.2006.10.001

William N. Hait , Eric Rubin , Elizabeth Alli , Susan Goodin

引用次数: 52

Central nervous system tumors 中枢神经系统肿瘤

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/j.uct.2006.06.005

Lynn S. Ashby, Matthew M. Troester, William R. Shapiro

{"title":"Central nervous system tumors","authors":"Lynn S. Ashby, Matthew M. Troester, William R. Shapiro","doi":"10.1016/j.uct.2006.06.005","DOIUrl":"10.1016/j.uct.2006.06.005","url":null,"abstract":"<div><h3>Introduction</h3><p>Chemotherapy, immunotherapy, and biological response modifiers were tested in clinical trials for brain tumors. Results of these studies published in 2003 and 2004 are reviewed.</p></div><div><h3>Materials and methods</h3><p>Major peer-reviewed journals in the disciplines of neurosurgery, neurology, medical oncology, and radiation oncology were surveyed. Results of phase II and phase III clinical trials testing chemotherapy, gene therapy, immunotherapy, and radiosensitizers for adults and children with malignant and low-grade glioma, primary central nervous system lymphoma (PCNSL), brain metastasis, medulloblastoma/primitive neuroectodermal tumor (PNET), and germ cell tumors were reviewed.</p></div><div><h3>Results</h3><p>Nitrosourea and temozolomide were tested as monotherapy or in combination with other agents as neoadjuvant, concurrent, and adjuvant treatment with radiotherapy for newly diagnosed malignant glioma in adults, including high-risk treatment groups, such as the elderly. Trials for recurrent malignant glioma included novel therapies, dendritic vaccine therapy, gene therapy and immunotherapy. High-dose chemotherapy with bone marrow rescue was tested in anaplastic oligodendroglioma (AO). Seven additional studies were performed to treat recurrent oligodendroglioma (O). Nine clinical trials for PCNSL emphasized the use of high-dose systemic methotrexate, temozolomide, and rituxin. Chemotherapy and immunotherapy were used to treat low-grade glioma in 7 studies. Intra-arterial and (IT) chemotherapy were used for metastatic disease. Treatment protocols for children were compared using multi-agent chemotherapy for malignant glioma, brainstem glioma, medulloblastoma, and germ cell tumors.</p></div><div><h3>Conclusion</h3><p>Multi-agent chemotherapy is successful for some pediatric brain tumors and PCNSL in adults. Vaccine, immunotherapy, and other gene therapies are still under investigation. Temozolomide and nitrosourea, specifically degradable polymer wafers, had the best results for malignant gliomas in adults. Treatment standards have been established for medulloblastoma/PNET. Treating malignant glioma in children remains problematic.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2006.06.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"55737884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Copyright text 版权文本

Update on cancer therapeutics Pub Date : 2006-12-01 DOI: 10.1016/S1872-115X(06)00072-7

引用次数: 0